短暂稳定而非抑制MYC可放大外源性凋亡并增强难治性B细胞淋巴瘤治疗反应
研究探讨MYC沉默对标准化疗的影响,发现抑制MYC转录使B淋巴母细胞对化疗耐药。通过药物抑制GSK-3β短暂稳定Myc蛋白,可增强多柔比星等药物在难治性伯基特淋巴瘤细胞系、患者来源异种移植及小鼠淋巴瘤同种移植中的凋亡,并依赖外源性死亡受体通路。
要点
- 抑制MYC转录使B淋巴母细胞对化疗药物耐药。
- GSK-3β抑制剂短暂稳定Myc可增强多柔比星诱导的凋亡。
- GSK3i还与TRAIL及mapatumumab协同杀伤淋巴瘤细胞。
核心结论
- 在化疗背景下,短暂稳定Myc蛋白可能比其失活更有益,GSK3i与标准化疗及死亡受体直接激动剂协同,可能改善难治性淋巴瘤患者的结局。
研究设计与样本
- 研究使用B淋巴母细胞、化疗难治性伯基特淋巴瘤细胞系、伯基特淋巴瘤患者来源异种移植和小鼠MYC驱动淋巴瘤同种移植进行体外和体内实验。
主要发现
- 抑制MYC转录使B淋巴母细胞对化疗药物耐药。
- 在化疗难治性伯基特淋巴瘤细胞系中,Myc短暂稳定后对多柔比星和其他抗癌药物的反应更好。
- 体内实验中,GSK3抑制剂增强多柔比星在伯基特淋巴瘤患者来源异种移植和小鼠MYC驱动淋巴瘤同种移植中诱导的凋亡。
- 该增强作用伴随并需要外源性死亡受体介导凋亡通路中多个关键基因的失调。
- GSK3抑制剂还促进TRAIL和死亡受体激动剂mapatumumab对淋巴瘤细胞的杀伤。
临床怎么用
- 作者认为GSK3i与标准化疗药物及死亡受体直接结合剂协同,可能改善难治性淋巴瘤患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic targeting of initiating oncogenes is the mainstay of precision medicine. Considerable efforts have been expended toward silencing MYC, which drives many human cancers including Burkitt lymphomas (BL). Yet, the effects of MYC silencing on standard-of-care therapies are poorly understood. Here we found that inhibition of MYC transcription renders B-lymphoblastoid cells refractory to chemotherapeutic agents. This suggested that in the context of chemotherapy, stabilization of Myc protein could be more beneficial than its inactivation. We tested this hypothesis by pharmacologically inhibiting glycogen synthase kinase 3β (GSK-3β), which normally targets Myc for proteasomal degradation. We discovered that chemorefractory BL cell lines responded better to doxorubicin and other anti-cancer drugs when Myc was transiently stabilized. In vivo, GSK3 inhibitors (GSK3i) enhanced doxorubicin-induced apoptosis in BL patient-derived xenografts (BL-PDX), as well as in murine MYC-driven lymphoma allografts. This enhancement was accompanied by and required deregulation of several key genes acting in the extrinsic, death-receptor-mediated apoptotic pathway. Consistent with this mechanism of action, GSK3i also facilitated lymphoma cell killing by a death ligand TRAIL and by a death receptor agonist mapatumumab. Thus, GSK3i synergizes with both standard chemotherapeutics and direct engagers of death receptors and could improve outcomes in patients with refractory lymphomas.
引用
- Harrington CT, Sotillo E, Robert A, et al. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia. 2019. PMID: 30914792. doi:10.1038/s41375-019-0454-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。